Literature DB >> 9389386

Phosphodiesterase type 4 that regulates cAMP level in cortical neurons shows high sensitivity to rolipram.

N Yamashita1, M Yamauchi, J Baba, A Sawa.   

Abstract

To characterize the role of phosphodiesterase type 4 (a cAMP-specific and rolipram-sensitive phosphodiesterase) among phosphodiesterases in the regulation of the intracellular cAMP level in cortical neurons, we investigated the effects of phosphodiesterase inhibitors on the intracellular cAMP levels in primary cultured rat cortical neurons. Selective inhibitors of phosphodiesterase type 4 and type 2 significantly enhanced beta-adrenoceptor-mediated cAMP increase. Selective inhibitors of phosphodiesterase type 1, type 3 and type 5/6 had no effect on the cAMP level. Rolipram enhanced the beta-adrenoceptor-mediated cAMP increase in cortical neurons, astrocytes and vascular smooth muscle cells at different minimum effective concentrations (10, 100 and 1000 nM, respectively). These findings indicate that phosphodiesterase type 4, showing a high-sensitivity to rolipram, plays a major role in regulating cAMP in the cortical neurons, and that rolipram at low doses enhances the intracellular cAMP increase in the cortical neurons selectively.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389386     DOI: 10.1016/s0014-2999(97)01285-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Activation of α7 nicotinic acetylcholine receptors increases intracellular cAMP levels via activation of AC1 in hippocampal neurons.

Authors:  Qing Cheng; Jerrel L Yakel
Journal:  Neuropharmacology       Date:  2015-04-29       Impact factor: 5.250

2.  Striatal neurones have a specific ability to respond to phasic dopamine release.

Authors:  Liliana R V Castro; Marina Brito; Elvire Guiot; Marina Polito; Christoph W Korn; Denis Hervé; Jean-Antoine Girault; Danièle Paupardin-Tritsch; Pierre Vincent
Journal:  J Physiol       Date:  2013-04-03       Impact factor: 5.182

3.  Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.

Authors:  Han-Ting Zhang; Ying Huang; Kathleen Mishler; Sandra C Roerig; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

4.  Disrupted-in-Schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade.

Authors:  Saurav Seshadri; Atsushi Kamiya; Yukako Yokota; Ingrid Prikulis; Shin-ichi Kano; Akiko Hayashi-Takagi; Amelia Stanco; Tae-Yeon Eom; Sarada Rao; Koko Ishizuka; Philip Wong; Carsten Korth; E S Anton; Akira Sawa
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

5.  Activity-based therapies to promote forelimb use after a cervical spinal cord injury.

Authors:  Haining Dai; Linda MacArthur; Marietta McAtee; Nicole Hockenbury; J Lille Tidwell; Brian McHugh; Kevin Mansfield; Tom Finn; Frank P T Hamers; Barbara S Bregman
Journal:  J Neurotrauma       Date:  2009-10       Impact factor: 5.269

6.  Penile Erection Induced by Scoparone from Artemisia capillaris through the Nitric Oxide-Cyclic Guanosine Monophosphate Signaling Pathway.

Authors:  Bo Ram Choi; Hye Kyung Kim; Jong Kwan Park
Journal:  World J Mens Health       Date:  2017-11-21       Impact factor: 5.400

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.